TY - JOUR
T1 - BET bromodomain inhibition of MYC-amplified medulloblastoma
AU - Bandopadhayay, Pratiti
AU - Bergthold, Guillaume
AU - Nguyen, Brian
AU - Schubert, Simone
AU - Gholamin, Sharareh
AU - Tang, Yujie
AU - Bolin, Sara
AU - Schumacher, Steven E.
AU - Zeid, Rhamy
AU - Masoud, Sabran
AU - Yu, Furong
AU - Vue, Nujsaubnusi
AU - Gibson, William J.
AU - Paolella, Brenton R.
AU - Mitra, Siddhartha S.
AU - Cheshier, Samuel H.
AU - Qi, Jun
AU - Liu, Kun Wei
AU - Wechsler-Reya, Robert
AU - Weiss, William A.
AU - Swartling, Fredrik J.
AU - Kieran, Mark W.
AU - Bradner, James E.
AU - Beroukhim, Rameen
AU - Cho, Yoon Jae
PY - 2014
Y1 - 2014
N2 - Purpose: MYC-amplified medulloblastomas are highly lethal tumors. Bromodomain and extraterminal (BET) bromodomain inhibition has recently been shown to suppress MYC-associated transcriptional activity in other cancers. The compound JQ1 inhibits BET bromodomain-containing proteins, including BRD4. Here, we investigate BET bromodomain targeting for the treatment of MYC-amplified medulloblastoma. Experimental Design: We evaluated the effects of genetic and pharmacologic inhibition of BET bromodomains on proliferation, cell cycle, and apoptosis in established and newly generated patientand genetically engineered mouse model (GEMM)-derived medulloblastoma cell lines and xenografts that harbored amplifications of MYC orMYCN. We also assessed the effect of JQ1 onMYC expression and global MYC-associated transcriptional activity. We assessed the in vivo efficacy of JQ1 in orthotopic xenografts established in immunocompromised mice. Results: Treatment of MYC-amplified medulloblastoma cells with JQ1 decreased cell viability associated with arrest at G1 and apoptosis. We observed downregulation of MYC expression and confirmed the inhibition of MYC-associated transcriptional targets. The exogenous expression of MYC from a retroviral promoter reduced the effect of JQ1 on cell viability, suggesting that attenuated levels of MYC contribute to the functional effects of JQ1. JQ1 significantly prolonged the survival of orthotopic xenograft models of MYC-amplified medulloblastoma (P < 0.001). Xenografts harvested from mice after five doses of JQ1 had reduced the expression of MYC mRNA and a reduced proliferative index. Conclusion: JQ1 suppresses MYC expression and MYC-associated transcriptional activity in medulloblastomas, resulting in an overall decrease in medulloblastoma cell viability. These preclinical findings highlight the promise of BET bromodomain inhibitors as novel agents for MYC-amplified medulloblastoma.
AB - Purpose: MYC-amplified medulloblastomas are highly lethal tumors. Bromodomain and extraterminal (BET) bromodomain inhibition has recently been shown to suppress MYC-associated transcriptional activity in other cancers. The compound JQ1 inhibits BET bromodomain-containing proteins, including BRD4. Here, we investigate BET bromodomain targeting for the treatment of MYC-amplified medulloblastoma. Experimental Design: We evaluated the effects of genetic and pharmacologic inhibition of BET bromodomains on proliferation, cell cycle, and apoptosis in established and newly generated patientand genetically engineered mouse model (GEMM)-derived medulloblastoma cell lines and xenografts that harbored amplifications of MYC orMYCN. We also assessed the effect of JQ1 onMYC expression and global MYC-associated transcriptional activity. We assessed the in vivo efficacy of JQ1 in orthotopic xenografts established in immunocompromised mice. Results: Treatment of MYC-amplified medulloblastoma cells with JQ1 decreased cell viability associated with arrest at G1 and apoptosis. We observed downregulation of MYC expression and confirmed the inhibition of MYC-associated transcriptional targets. The exogenous expression of MYC from a retroviral promoter reduced the effect of JQ1 on cell viability, suggesting that attenuated levels of MYC contribute to the functional effects of JQ1. JQ1 significantly prolonged the survival of orthotopic xenograft models of MYC-amplified medulloblastoma (P < 0.001). Xenografts harvested from mice after five doses of JQ1 had reduced the expression of MYC mRNA and a reduced proliferative index. Conclusion: JQ1 suppresses MYC expression and MYC-associated transcriptional activity in medulloblastomas, resulting in an overall decrease in medulloblastoma cell viability. These preclinical findings highlight the promise of BET bromodomain inhibitors as novel agents for MYC-amplified medulloblastoma.
UR - http://www.scopus.com/inward/record.url?scp=84896714612&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896714612&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-13-2281
DO - 10.1158/1078-0432.CCR-13-2281
M3 - Article
C2 - 24297863
AN - SCOPUS:84896714612
SN - 1078-0432
VL - 20
SP - 912
EP - 925
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 4
ER -